Testosterone Therapy Shows Promise for Prostate Cancer Survivors After Radiation

For decades, doctors have avoided testosterone replacement therapy in prostate cancer survivors, fearing it might fuel cancer recurrence. This new research suggests that approach may be overly cautious, potentially denying men important health benefits.

Researchers at Harvard Medical School studied 33 prostate cancer survivors (median age 75) who received testosterone therapy after radiation treatment. All men had confirmed low testosterone and were followed for cancer recurrence and symptom improvement.

Testosterone levels increased dramatically from 66 to 299 ng/dL, bringing most men into normal ranges. While prostate-specific antigen (PSA) levels rose slightly from 0.04 to 0.17 ng/mL, they remained very low. Only one patient (3%) developed metastatic disease three years after starting therapy. A review of published studies showed similarly low recurrence rates of 3.3% over 42 months.

The benefits were substantial: patients reported improvements in fatigue, mood, and sexual function. Nearly half of men with anemia saw their condition resolve, which is significant since anemia increases mortality risk and reduces quality of life in older adults.

These findings have important implications for healthy aging. Low testosterone contributes to muscle loss, bone weakness, cognitive decline, and cardiovascular problems. For prostate cancer survivors experiencing these issues, testosterone therapy might offer meaningful benefits with acceptable risks.

However, this was a small observational study without a control group. The researchers acknowledge that randomized controlled trials are needed to definitively establish safety and efficacy before changing clinical practice.